Fortuna Haviv

This inventor holds 36 USPTO granted patents, plus 2 CIPO patents and 1 EPO patent, primarily in Peptide Therapeutics. Top assignees: Abbott Laboratories Corporation, Tap Holdings, LLC, Tap Pharmaceuticals, Inc.. Active years: 1981-2009.

USPTO Granted Patents = 36

% Patents Active = 86.1

CIPO Patents = 2 (Patent Applications = 13)

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 3.0

ph-index = 8

Forward Citations = 264(Granted Patents)

Location History:

Vernon Hills, IL (US) (1981 - 1982)
Dearfield, IL (US) (1983)
Deerfield, IL (US) (1983 - 2009)

Company Filing History:

28 out of 4,186

Abbott Laboratories Corporation

Tap Pharmaceuticals, Inc.

5. 1 out of 834,411

Other

patents

Years Active: 1981-2009

Loading Chart...

Areas of Expertise:

Antiangiogenic Peptides

LHRH Antagonists

Peptide Formulations

Macrolide Derivatives

Alkaline Phosphatase Inhibitors

Tetra-, Penta-, Hexapeptides

Cyclic Peptides

Modified Aminoacyl Residues

Inflammatory Condition Treatment

N-terminus Modifications

Peptide Analogues

Therapeutic Compounds

36 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7592466 - Ureas having antiangiogenic activity (2009-09-22),

2. 7432245 - Pharmaceutical formulation comprising a peptide angiogenesis inhibitor (2008-10-07),

3. 7169888 - Tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity (2007-01-30),

4. 7122625 - Hexa-, hepta-, and octapeptides having antiangiogenic activity (2006-10-17),

5. 7067490 - Hepta-, Octa-and nonapeptides having antiangiogenic activity (2006-06-27),

6. 7037897 - TRI-, TETRA-, and penta-peptides having antiangiogenic activity (2006-05-02),

7. 7001984 - Di-, tri-, and tetra-peptides having antiangiogenic activity (2006-02-21),

8. 6777535 - N-alkylated peptides having antiangiogenic activity (2004-08-17),

9. 6774211 - Peptide antiangiogenic drugs (2004-08-10),

10. 6753408 - Peptides having antiangiogenic activity (2004-06-22),

11. 6716963 - Peptide antiangiogenic drugs (2004-04-06),

12. 6387885 - 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists (2002-05-14),

13. 6297354 - Pentapeptide LHRH antagonists (2001-10-02),

14. 6191115 - C-terminus modified heptapeptide LHRH analogs (2001-02-20),

15. 6020521 - Macrolide LHRH antagonists (2000-02-01),

Title: Fortuna Haviv: Innovator in Antiangiogenic Compounds

Introduction

Fortuna Haviv, based in Deerfield, IL, is a notable inventor with a strong portfolio comprising 36 patents. His work primarily focuses on pharmaceutical formulations and compounds that demonstrate antiangiogenic activity, contributing significantly to advancements in medicinal chemistry.

Latest Patents

Haviv's latest patents delve into groundbreaking innovations in the field of antiangiogenic treatments. One of his notable patents involves "Ureas having antiangiogenic activity," where he provides compositions and methods for creating compounds that inhibit angiogenesis. Additionally, he has developed a patent for "Pharmaceutical formulation comprising a peptide angiogenesis inhibitor," detailing parenteral formulations of peptides designed for sustained release, along with the methods for their preparation.

Career Highlights

Throughout his career, Fortuna Haviv has collaborated with prominent organizations such as Abbott Laboratories and Tap Pharmaceuticals. His tenure in these companies has allowed him to push the boundaries of pharmaceutical innovations, focusing on therapies that address various medical challenges.

Collaborations

During his professional journey, Haviv has worked alongside distinguished colleagues, including Jonathan Greer and Michael F. Bradley. These collaborations have fostered an environment of creativity and innovation, leading to numerous advancements in drug development and therapy.

Conclusion

Fortuna Haviv's contributions to the field of pharmaceuticals underscore the importance of innovation in creating effective medical treatments. With his impressive patent portfolio and collaborative spirit, he continues to be a key figure in the pursuit of new solutions for significant health issues.